NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Price Target & More

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.08. The biopharmaceutical company earned $44.28 million during the quarter, compared to the consensus estimate of $44 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. The company's revenue was up 15.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.08 earnings per share. View Vanda Pharmaceuticals' Earnings History.

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Vanda Pharmaceuticals.

5 Wall Street analysts have issued 12-month price targets for Vanda Pharmaceuticals' stock. Their forecasts range from $18.00 to $27.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $22.40 in the next year. View Analyst Ratings for Vanda Pharmaceuticals.

Vanda Pharmaceuticals saw a drop in short interest during the month of March. As of March 29th, there was short interest totalling 2,380,973 shares, a drop of 29.3% from the March 15th total of 3,367,547 shares. Based on an average daily trading volume, of 1,242,810 shares, the days-to-cover ratio is currently 1.9 days. Currently, 4.9% of the company's shares are sold short.

Some companies that are related to Vanda Pharmaceuticals include Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD), Akorn (AKRX), Puma Biotechnology (PBYI), Horizon Pharma (HZNP) and Heron Therapeutics (HRTX).

Media headlines about VNDA stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of 0.13 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 49.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $14.95.

Vanda Pharmaceuticals has a market capitalization of $749.01 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]